ArticleLipids in health and disease2026
Lysophosphatidylcholine 18:2 exacerbates Th17-dominant inflammation in obese asthma.
Article in Lipids in health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundObese asthma is increasingly recognized as a distinct clinical phenotype, often associated with greater disease severity and non-type 2-skewed inflammation. Obesity-associated lipid dysregulation may contribute to its pathogenesis through immunomodulatory mechanisms. This study aimed to characterize the glycerophospholipid profile of obese asthma and to investigate the functional impact of candidate lipids on immune responses.
methodsWe performed targeted lipidomic analysis of serum glycerophospholipids in patients with overweight/obese asthma and those with normal-weight asthma. A house dust mite (HDM)-induced asthma model was established in diet-induced obese (DIO) mice to evaluate pulmonary pathology and T-cell immune polarization. The immunomodulatory effects of lysophosphatidylcholine (LPC) 18:2 were assessed using in vivo experiments and in vitro T helper 17 (Th17) differentiation assays. Cellular uptake of LPC by naïve CD4⁺ T cells was quantified to explore the mechanism underlying the reduced circulating abundance of LPC 18:2.
resultsLipidomic profiling revealed a differential glycerophospholipid signature in obese asthma, with LPC 18:2 exhibiting the most pronounced reduction. Obese asthmatic mice exhibited exacerbated airway inflammation consistent with a Th17-skewed immune response. Despite reduced circulating levels, administration of exogenous LPC 18:2 further aggravated airway inflammation and selectively enhanced Th17 polarization in these mice. In vitro assays confirmed that LPC 18:2 directly promotes Th17 differentiation in a dose-dependent manner. Mechanistically, naïve CD4⁺ T cells from obese mice showed increased LPC uptake, potentially explaining both the reduced circulating LPC 18:2 levels and its amplified pro-inflammatory effects in obese asthma.
conclusionsOur findings highlight LPC 18:2 as a potential metabolic regulator that may link obesity-associated lipid disturbances to pathological Th17-skewed immune responses. Modulation of LPC 18:2-related pathways may therefore represent a novel therapeutic strategy for this asthma phenotype.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.